Celgene Wins Chinese Approval for Revlimid

Biotech company Celgene (NASDAQ: CELG  ) has announced that its subsidiary Celgene International Sàrl has won full regulatory approval from the China State Food and Drug Administration for Revlimid.

Revlimid, used to treat relapsed or refractory multiple myeloma in patients who have already undergone at least one therapy, is expected to be available to Chinese patients sometime late in the second quarter. The drug, which is already approved in numerous other locations, recorded more than $3.7 billion in sales in 2012.

Additionally, Celgene said in the press release that the U.S. Food and Drug Administration has assigned a priority review to the company's filing to use Revlimid to treat patients with relapsed or refractory mantle cell lymphoma. The FDA's decision date of that filing has been set for June 5.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2253506, ~/Articles/ArticleHandler.aspx, 4/17/2014 3:09:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement